Company intelligence / Profile preview

Vantia Therapeutics

Southampton/Chilworth, Hampshire, United Kingdomvantiatherapeutics.com ↗

Ownership: Private
Employees: ~4
Development stage: Phase 2

Overview

Vantia Therapeutics was a UK-based biotech/pharma company specializing in the development of novel small molecule drugs targeting large unmet medical needs in urology and women’s health. Its most advanced program was fedovapagon for nocturia, which reached Phase III clinical trials. The company also developed assets for dysmenorrhoea and other indications but ultimately ceased operations after raising approximately $44M.

Therapeutic areas: NephrologyOphthalmologyImmunologyWomen's HealthOncology
Modalities: Small moleculesSynthetic peptides
Industry: Biotech

Drug pipeline

2 assets

fedovapagon

1 more asset in the full pipeline.

Beyond the preview

Go deeper on Vantia Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vantia Therapeutics.